Perspective Therapeutics to Participate in Upcoming September Conferences

Core Insights - Perspective Therapeutics, Inc. is a radiopharmaceutical company focused on advanced cancer treatments using proprietary technology that employs the alpha-emitting isotope Pb to target cancer cells specifically [3][4] - The company is actively participating in several upcoming healthcare conferences to engage with investors and discuss its innovative therapies [1][2] Company Overview - Perspective Therapeutics is pioneering advanced treatments for various cancers, utilizing a "theranostic" approach that combines therapy and diagnostics to personalize treatment and optimize patient outcomes [3] - The company is developing imaging diagnostics that work alongside its therapeutic products, enhancing the ability to visualize and treat tumors effectively [3] Clinical Development - The company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are currently in Phase 1/2a imaging and therapy trials in the U.S. [4] - Perspective Therapeutics is expanding its regional network of drug product candidate finishing facilities, supported by its proprietary Pb generator, to ensure the delivery of patient-ready products for clinical trials and commercial operations [4]